Innaxon Therapeutics

Innaxon Therapeutics is a biopharmaceutical company focused on developing novel therapeutics that modulate the innate immune system, specifically targeting Toll-like receptors (TLRs). The company leverages its expertise in TLR biology to design small molecules and oligonucleotides that can either inhibit or activate specific immune pathways. Their lead programs focus on TLR7, TLR8, and TLR9 antagonists for the treatment of autoimmune and inflammatory disorders such as systemic lupus erythematosus. Additionally, Innaxon is exploring TLR4 antagonists for conditions like sepsis and acute inflammation. By precisely targeting these receptors, the company aims to provide more effective treatments for diseases with high unmet medical needs.